An item on investing blog Seeking Alpha advises readers not to own stock in the pharmaceutical company Merck, in part because of safety risks associated with its products.
The item mentions a recent study published in the medical journal JAMA Internal Medicine. Researchers concluded that a type of drugs for type 2 diabetes called GLP-1 atagonists, which include Merck’s Januvia and Bristol-Myers Squibb’s Byetta, double a patient’s chances of developing pancreatitis. ...
continue reading...